JP2023071827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023071827A5 JP2023071827A5 JP2023030635A JP2023030635A JP2023071827A5 JP 2023071827 A5 JP2023071827 A5 JP 2023071827A5 JP 2023030635 A JP2023030635 A JP 2023030635A JP 2023030635 A JP2023030635 A JP 2023030635A JP 2023071827 A5 JP2023071827 A5 JP 2023071827A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- pharmaceutical composition
- composition according
- disease
- glp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024159697A JP7789871B2 (ja) | 2017-09-22 | 2024-09-17 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562283P | 2017-09-22 | 2017-09-22 | |
| US62/562,283 | 2017-09-22 | ||
| JP2020516667A JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| PCT/US2018/052110 WO2019060653A1 (en) | 2017-09-22 | 2018-09-21 | GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516667A Division JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159697A Division JP7789871B2 (ja) | 2017-09-22 | 2024-09-17 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023071827A JP2023071827A (ja) | 2023-05-23 |
| JP2023071827A5 true JP2023071827A5 (enExample) | 2023-10-11 |
| JP7559112B2 JP7559112B2 (ja) | 2024-10-01 |
Family
ID=63799082
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516667A Active JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| JP2023030635A Active JP7559112B2 (ja) | 2017-09-22 | 2023-03-01 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| JP2024159697A Active JP7789871B2 (ja) | 2017-09-22 | 2024-09-17 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516667A Active JP7239566B2 (ja) | 2017-09-22 | 2018-09-21 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159697A Active JP7789871B2 (ja) | 2017-09-22 | 2024-09-17 | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11045522B2 (enExample) |
| EP (1) | EP3684793A1 (enExample) |
| JP (3) | JP7239566B2 (enExample) |
| KR (1) | KR102696518B1 (enExample) |
| CN (2) | CN118955732A (enExample) |
| AU (2) | AU2018338178B2 (enExample) |
| CA (1) | CA3073964A1 (enExample) |
| EA (1) | EA202090649A1 (enExample) |
| IL (2) | IL273253B2 (enExample) |
| MX (1) | MX2020002977A (enExample) |
| MY (2) | MY207828A (enExample) |
| SG (1) | SG11202001637PA (enExample) |
| WO (1) | WO2019060653A1 (enExample) |
| ZA (1) | ZA202001167B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7239566B2 (ja) * | 2017-09-22 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| WO2022119076A1 (ko) * | 2020-12-03 | 2022-06-09 | 이뮤노포지 주식회사 | Glp-1 수용체 작용제 및 항-오스카 항체를 포함하는 융합 단백질 및 이의 용도 |
| WO2022117044A1 (en) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof |
| CN112716966B (zh) * | 2021-02-03 | 2022-05-03 | 浙江诺得药业有限公司 | 一种恩格列净药用组合物及其制备方法 |
| CN113461785B (zh) * | 2021-04-13 | 2022-10-14 | 湖南中晟全肽生化有限公司 | Glp-1受体激动剂及其应用 |
| CN119638849A (zh) * | 2021-10-18 | 2025-03-18 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| CN114788876B (zh) * | 2022-02-24 | 2024-07-05 | 北京医院 | 治疗糖尿病的mRNA药物制剂及其制备方法与应用 |
| US20250289861A1 (en) * | 2022-05-04 | 2025-09-18 | Immunoforge Co.,Ltd. | Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250270274A1 (en) * | 2024-02-26 | 2025-08-28 | Serpentide Inc. | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| TW200843794A (en) | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| DK2373681T3 (en) | 2008-12-10 | 2017-04-24 | Glaxosmithkline Llc | PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| KR101229610B1 (ko) * | 2009-10-09 | 2013-02-05 | 한남대학교 산학협력단 | Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물 |
| WO2011056644A2 (en) | 2009-10-28 | 2011-05-12 | Centocor Ortho Biotech Inc. | Anti-glp-1r antibodies and their uses |
| WO2011056713A2 (en) | 2009-11-03 | 2011-05-12 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| CA2880929A1 (en) | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| WO2014113357A1 (en) | 2013-01-17 | 2014-07-24 | Transtech Pharma, Llc | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
| US20150259416A1 (en) | 2014-03-12 | 2015-09-17 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| CN104098702B (zh) * | 2014-07-23 | 2017-06-16 | 湖北工业大学 | 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用 |
| CN104645317B (zh) * | 2015-01-28 | 2020-04-17 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物 |
| ES2833099T3 (es) | 2015-02-11 | 2021-06-14 | Gmax Biopharm Llc | Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| AU2017277594A1 (en) * | 2016-06-09 | 2019-02-07 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| JP7239566B2 (ja) * | 2017-09-22 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
-
2018
- 2018-09-21 JP JP2020516667A patent/JP7239566B2/ja active Active
- 2018-09-21 EP EP18783613.5A patent/EP3684793A1/en active Pending
- 2018-09-21 CN CN202410964216.3A patent/CN118955732A/zh active Pending
- 2018-09-21 MX MX2020002977A patent/MX2020002977A/es unknown
- 2018-09-21 IL IL273253A patent/IL273253B2/en unknown
- 2018-09-21 SG SG11202001637PA patent/SG11202001637PA/en unknown
- 2018-09-21 CN CN201880061327.6A patent/CN111108117B/zh active Active
- 2018-09-21 CA CA3073964A patent/CA3073964A1/en active Pending
- 2018-09-21 EA EA202090649A patent/EA202090649A1/ru unknown
- 2018-09-21 US US16/137,662 patent/US11045522B2/en active Active
- 2018-09-21 MY MYPI2023002759A patent/MY207828A/en unknown
- 2018-09-21 KR KR1020207011414A patent/KR102696518B1/ko active Active
- 2018-09-21 IL IL304574A patent/IL304574B2/en unknown
- 2018-09-21 MY MYPI2020000984A patent/MY200364A/en unknown
- 2018-09-21 WO PCT/US2018/052110 patent/WO2019060653A1/en not_active Ceased
- 2018-09-21 AU AU2018338178A patent/AU2018338178B2/en active Active
-
2020
- 2020-02-25 ZA ZA2020/01167A patent/ZA202001167B/en unknown
-
2021
- 2021-05-27 US US17/332,215 patent/US11779633B2/en active Active
-
2023
- 2023-03-01 JP JP2023030635A patent/JP7559112B2/ja active Active
- 2023-08-29 US US18/457,482 patent/US12090193B2/en active Active
- 2023-09-04 AU AU2023223010A patent/AU2023223010B2/en active Active
-
2024
- 2024-08-14 US US18/804,421 patent/US20250000949A1/en active Pending
- 2024-09-17 JP JP2024159697A patent/JP7789871B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tahrani et al. | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus | |
| JP7642588B2 (ja) | 療法のためｇｉｐ／ｇｌｐ１コアゴニストを使用する方法 | |
| JP7789871B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| Choe et al. | Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists | |
| Levien et al. | New drugs in development for the treatment of diabetes. | |
| JP2010031018A5 (enExample) | ||
| Rajeev et al. | GLP-1 as a target for therapeutic intervention | |
| TW201247702A (en) | Use of acylated glucagon analogues | |
| KR20090088854A (ko) | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 | |
| Nauck et al. | Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits | |
| WO2023228023A1 (en) | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JP2019535791A (ja) | 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク | |
| AU2020344895B2 (en) | Treatment of type 2 diabetes mellitus | |
| CN117915914A (zh) | 治疗肝病的组合疗法 | |
| RU2679602C1 (ru) | Состав для лечения сахарного диабета | |
| Gorecka et al. | Biological and biosimilar medicines in contemporary pharmacotherapy for metabolic syndrome | |
| Kaur et al. | Hormones and hormones antagonists | |
| WO2024027553A1 (zh) | 一种双功能融合蛋白及其用途 | |
| Morales et al. | The use of SGLT2 inhibitors and GLP-1 receptor agonists, a worthwhile physiologic combination in managing type 2 diabetes while reducing cardiovascular risk | |
| WO2025213190A1 (en) | Methods of treating a disease or condition associated with weight gain | |
| AU2009238272B2 (en) | Method of treatment of diabetes type 2 comprising add-on therapy to metformin | |
| Islam | A review on synthesis, characterization, and pharmacological evaluation of second-line antidiabetic drugs | |
| WO2026072993A1 (en) | Methods for treatment of metabolic dysfunction-associated steatohepatitis with an anti-tl1a antibody | |
| RU2022104898A (ru) | Слитый белок fgf21 fc, слитый белок glp-1 fc и комбинированный терапевтический агент, включающий их, и их применение |